Blueshift Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Blueshift Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-898	Closed	-$349K	–	1001
2021 Q2	$349K	Buy	+898	New	+$320K	0.02%	680
2021 Q1	–	Sell	-513	Closed	-$252K	–	851
2020 Q4	$252K	Buy	+513	New	+$237K	0.03%	563

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blueshift Asset Management's ATRA Position: Q3 2021 in Review

Blueshift Asset Management sold out of Atara Biotherapeutics (ATRA) in Q3 2021, closing a stake of 898 shares — an estimated $349K sold.

Blueshift Asset Management first reported a position in ATRA in Q4 2020 and held it in 2 quarters. The position peaked at $349K in Q2 2021. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

Blueshift Asset Management reported no remaining Atara Biotherapeutics position as of Q3 2021 after selling out during the quarter.
Blueshift Asset Management sold 898 Atara Biotherapeutics shares in Q3 2021, an estimated $349K.
Blueshift Asset Management first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 2 quarters.
Blueshift Asset Management's Atara Biotherapeutics position peaked at $349K in Q2 2021.
140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.